Skip to main content

ADVERTISEMENT

Videos

David Andorsky, MD, Rocky Mountain Cancer Centers
Conference Coverage
06/03/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.
David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.
David Andorsky, MD, discussed...
06/03/2024
Oncology
Miguel Regueiro MD
Conference Coverage
06/03/2024
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results...
06/03/2024
Advances in Inflammatory Bowel Disease Network
Jane Meisel, MD
Conference Coverage
06/02/2024
Jane Meisel, MD
Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.
Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.
Jane Meisel, MD, discusses the...
06/02/2024
Oncology
Suresh Ramalingam, MD
Conference Coverage
06/02/2024
Suresh Ramalingam, MD
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology
Videos
06/01/2024
Corey Langer, MD
Corey Langer, MD, discusses treatment options for a patient with early-stage non-small cell lung cancer with a PD-L1 of 80%.
Corey Langer, MD, discusses treatment options for a patient with early-stage non-small cell lung cancer with a PD-L1 of 80%.
Corey Langer, MD, discusses...
06/01/2024
Oncology
Areej El-Jawahri, MD, Massachusetts General Hospital
Conference Coverage
06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses...
06/01/2024
Oncology
Daniel Petrylak, MD
Conference Coverage
06/01/2024
Daniel Petrylak, MD
Daniel Petrylak, MD, discussed results from a phase 1/2 study that demonstrated that ARV-766 was well tolerated and showed promising clinical activity among patients with androgen receptor LBD-mutated metastatic castration-resistant prostate...
Daniel Petrylak, MD, discussed results from a phase 1/2 study that demonstrated that ARV-766 was well tolerated and showed promising clinical activity among patients with androgen receptor LBD-mutated metastatic castration-resistant prostate...
Daniel Petrylak, MD, discussed...
06/01/2024
Oncology
Natasha Leighl, MD
Conference Coverage
06/01/2024
Natasha Leighl, MD
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
Videos
05/31/2024

Barry Russo, MBA, the Center for Cancer and Blood Disorders

Barry Russo, MBA, the Center for Canc...
Barry Russo, MBA, breaks down how collaboration between stakeholders leads to more comprehensive care in value-based care models.
Barry Russo, MBA, breaks down how collaboration between stakeholders leads to more comprehensive care in value-based care models.
Barry Russo, MBA, breaks down...
05/31/2024
Journal of Clinical Pathways
Triantafyllis Figure
Clinical Videos
05/30/2024

Konstantinos Antoniades, MD; Sotirios C. Kotoulas, MD; Dimitrios Iliopoulos, MD; Efthymia Koutsogiannaki, MD; Aimilianos Kalogeris, MD; Leonidas E. Poulimenos, MD; Andreas S. Triantafyllis, MD, PhD

Konstantinos Antoniades, MD; Sotirios...
Video Supplement to "Coronary Angiography Through the Interosseous Artery: Expanding the Limits of the Wrist Approach" (Clinical Image).
Video Supplement to "Coronary Angiography Through the Interosseous Artery: Expanding the Limits of the Wrist Approach" (Clinical Image).
Video Supplement to "Coronary...
05/30/2024
Journal of Invasive Cardiology